Core Insights - AIM ImmunoTech Inc. is focusing on advancing clinical trials of Ampligen® for pancreatic cancer treatment, aiming for drug approval [2][4] - The company reported a bolstered cash position, with funding expected to last approximately 12 months following a public equity offering that raised $8.0 million [10] - Positive mid-year data from the Phase 2 clinical study of Ampligen® in combination with AstraZeneca's Imfinzi® shows no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) [2][10] Financial Highlights - AIM ImmunoTech closed a public equity offering, raising $8.0 million in gross proceeds [10] - The company has regained its listing status on the NYSE American [10] Clinical Development - The ongoing Phase 2 study (DURIPANC) evaluates Ampligen® combined with Imfinzi® for metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX [10] - The company has received U.S. and EU Orphan Drug designations for pancreatic cancer [10] Intellectual Property - AIM ImmunoTech has been granted U.S. patents covering methods of manufacturing therapeutic dsRNA, including Ampligen, and for its combination with PD-L1 drugs for cancer treatment [10] Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® as its lead product [7]

Group 1 - AIM ImmunoTech Inc. announced the closing of a public offering of 2,000,000 shares of common stock and accompanying warrants at a combined public offering price of $4.00 per share, resulting in gross proceeds of approximately $8.0 million before expenses [1][2][3] - The offering included Class E and Class F warrants, both of which are exercisable immediately upon issuance, with Class E warrants expiring on the fifth anniversary and Class F warrants expiring on the eighteen-month anniversary of the original issuance date [1] - Maxim Group LLC acted as the sole placement agent for this offering [2] Group 2 - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), which is a first-in-class investigational drug with broad-spectrum activity in clinical trials [4]

Core Viewpoint - AIM ImmunoTech Inc. has announced a public offering of 2,000,000 shares of common stock and accompanying warrants, aiming to raise approximately $8.0 million before expenses [1]. Group 1: Offering Details - The public offering includes 2,000,000 shares of common stock or pre-funded warrants, along with Class E and Class F warrants, each allowing the purchase of up to 2,000,000 shares [1]. - The combined public offering price is set at $4.00 per share or $3.999 per pre-funded warrant, with warrants exercisable immediately upon issuance [1]. - Class E warrants will expire five years after issuance, while Class F warrants will expire eighteen months after issuance [1]. - The closing of the offering is expected around July 30, 2025, pending customary closing conditions [1]. Group 2: Financial and Regulatory Information - Gross proceeds from the offering are anticipated to be approximately $8.0 million before deducting placement agent fees and offering expenses [1]. - The offering is conducted under a registration statement on Form S-1, which was declared effective by the SEC on July 28, 2025 [3]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [5]. - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug with broad-spectrum activity in clinical trials [5].

Core Insights - AIM ImmunoTech Inc. reported positive mid-year data from the Phase 2 DURIPANC study, indicating promising signs of no significant toxicity and superior progression-free survival (PFS) and overall survival (OS) in metastatic pancreatic cancer patients treated with Ampligen® and durvalumab [1][3][5] Company Overview - AIM ImmunoTech is focused on developing therapeutics for various cancers, immune disorders, and viral diseases, with Ampligen® being its lead investigational drug [9] Study Details - The DURIPANC study is a collaboration with AstraZeneca and Erasmus Medical Center, aiming to evaluate the combination therapy of Ampligen and durvalumab in patients with stable disease post-FOLFIRINOX [1][4] - The study is expected to enroll up to 25 subjects, with 14 subjects enrolled as of the mid-year report [1] Preliminary Findings - The combination therapy has shown a well-tolerated safety profile, with approximately 21% of patients experiencing PFS greater than 6 months and 64% of eligible patients having OS greater than 6 months [5] - The study aims to assess clinical benefit rates, OS, PFS, and initiate immune-monitoring using tissue biopsies and immune profiling [1][2] Future Directions - Further analysis of immune-monitoring data is anticipated to provide insights into the biological activity and durability of response, as well as identify predictive biomarkers for patient selection [2][3] - The company has developed an intellectual property plan, including a U.S. patent for Ampligen as an oncology treatment, extending protection to August 9, 2039 [8]

Core Viewpoint - AIM ImmunoTech Inc. has secured a significant patent for the manufacturing of its drug Ampligen, extending patent protection until 2041, which enhances its control over the drug's synthesis and use in various therapeutic applications [1][2][3]. Patent Protection - The newly granted U.S. patent No. 12312376 covers methods for manufacturing a range of therapeutic double-stranded RNA products, including Ampligen, thereby strengthening AIM's intellectual property portfolio [1][2]. - AIM's overall patent portfolio includes protections for Ampligen in treating various conditions, with specific patents expiring between 2039 and 2042 [4]. Development and FDA Approval - The patent extension provides AIM with additional time to develop its drug program and pursue FDA approval for Ampligen across multiple indications, including cancers and viral diseases [3][5]. - AIM's intellectual property also includes multiple Orphan Drug Designations from the FDA and EMA, granting market exclusivity for seven to ten years post-approval for various conditions [5]. Company Overview - AIM ImmunoTech Inc. is focused on developing therapeutics for cancers, immune disorders, and viral diseases, with Ampligen being its lead investigational drug, demonstrating broad-spectrum activity in clinical trials [6].

Group 1 - AIM ImmunoTech Inc. announced a reverse stock split at a ratio of 1-for-100, effective June 12, 2025 [1] - The primary goal of the reverse stock split is to increase the per-share market price to regain compliance with NYSE American's Listing Qualifications [2] - Stockholders approved the reverse stock split at a Special Meeting on April 30, 2025, and will receive cash for any fractional shares post-split [3] Group 2 - AIM ImmunoTech Inc. focuses on the research and development of therapeutics for cancers, immune disorders, and viral diseases, including COVID-19 [4] - The company's lead product is Ampligen® (rintatolimod), an investigational drug with broad-spectrum activity in clinical trials [4]